{
    "name": "micafungin",
    "comment": "Rx",
    "other_names": [
        "Mycamine"
    ],
    "classes": [
        "Antifungals",
        "Systemic",
        "Antifungals",
        "Echinocandin"
    ],
    "source": "https://reference.medscape.com/drug/mycamine-micafungin-342585",
    "pregnancy": {
        "common": [
            "Based on findings from animal studies, may cause fetal harm when administered to pregnant women",
            "Human data are insufficient on use in pregnant women to inform a drug-associated risk of adverse developmental outcomes"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "In an embryo-fetal toxicity study in pregnant rabbits, IV administration during organogenesis resulted in fetal visceral abnormalities and abortion at 32 mg/kg, a dose equivalent to 4x times the recommended human dose based on body surface area comparisons",
                    "Visceral abnormalities included abnormal lobation of the lung, levocardia, retrocaval ureter, anomalous right subclavian artery, and dilatation of the ureter"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available regarding the presence of micafungin in human milk, effects on breastfed infants, or effects on milk production",
            "Micafungin was present in the milk of lactating rats following IV administration; when a drug is present in animal milk, it is likely that the drug will be present in human milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "NOT for IV bolus",
                "No data on effectiveness against fungi other than Candida",
                "Anaphylaxis and anaphylactoid reactions (including shock) reported; discontinue therapy and administer appropriate treatment",
                "Isolated cases of acute intravascular hemolysis, hemolytic anemia and hemoglobinuria reported; patients who develop clinical or laboratory evidence of hemolysis or hemolytic anemia during therapy should be monitored closely for evidence of worsening of these conditions and evaluated for risk/benefit of continuing therapy",
                "Abnormalities in liver function tests; isolated cases of hepatic impairment, hepatitis, and hepatic failure reported; in some patients with serious underlying conditions receiving therapy along with multiple concomitant medications, clinical hepatic abnormalities have occurred, and isolated cases of significant hepatic impairment, hepatitis, and hepatic failure reported; patients who develop abnormal liver function tests during therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing therapy",
                "Elevations in BUN and creatinine; isolated cases of renal impairment or acute renal failure reported; patients who develop abnormal renal function tests during therapy should be monitored for evidence of worsening renal function"
            ],
            "specific": [
                {
                    "type": "Infusion and injection site reactions",
                    "description": [
                        "Possible histamine-mediated symptoms reported. including rash, pruritus, facial swelling, and vasodilation; slow infusion rate if reactions occur",
                        "Injection site reactions, including phlebitis and thrombophlebitis reported; these reactions occur more often when administered via peripheral IV"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "micafungin will increase the level or effect of lonafarnib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Saccharomyces boulardii",
            "description": {
                "common": "micafungin decreases effects of Saccharomyces boulardii by unspecified interaction mechanism. Avoid or Use Alternate Drug. Systemic or oral antifungals may decrease activity of probiotic."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atogepant",
            "description": {
                "common": "micafungin will increase the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "micafungin will increase the level or effect of avapritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "axitinib",
            "description": {
                "common": "micafungin increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and micafungin both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "finerenone",
            "description": {
                "common": "micafungin will increase the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "micafungin will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "micafungin will increase the level or effect of isavuconazonium sulfate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivacaftor",
            "description": {
                "common": "micafungin increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "micafungin will increase the level or effect of lemborexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomitapide",
            "description": {
                "common": "micafungin increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "micafungin will increase the level or effect of midazolam intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nifedipine",
            "description": {
                "common": "micafungin increases levels of nifedipine by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sirolimus",
            "description": {
                "common": "micafungin increases levels of sirolimus by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "micafungin will increase the level or effect of tazemetostat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tinidazole",
            "description": {
                "common": "micafungin will increase the level or effect of tinidazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, micafungin.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "micafungin will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "micafungin will increase the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Abd pain",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Increased LFTs",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Neutropenia",
            "percent": null
        },
        {
            "name": "Phlebitis",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Rigors",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Facial swelling",
            "percent": null
        },
        {
            "name": "Vasodilation",
            "percent": null
        },
        {
            "name": "Delirium",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Somnolence",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system disorders",
            "percent": null
        },
        {
            "name": "white blood cell count decreased",
            "percent": null
        },
        {
            "name": "hemolytic anemia",
            "percent": null
        },
        {
            "name": "disseminated intravascular coagulation",
            "percent": null
        },
        {
            "name": "Hepatobiliary disorders",
            "percent": null
        },
        {
            "name": "hyperbilirubinemia",
            "percent": null
        },
        {
            "name": "hepatic function abnormal",
            "percent": null
        },
        {
            "name": "hepatic disorder",
            "percent": null
        },
        {
            "name": "hepatocellular damage",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "acute renal failure and renal impairment",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "toxic epidermal necrolysis",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "shock",
            "percent": null
        }
    ]
}